PharmaCyte Biotech, Inc. Cash Flow Statement
PMCB|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
PharmaCyte Biotech, Inc. used $2M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $333.8K | -$4.3M | -$4.2M | -$3.6M | -$3.8M | -$4.1M | -$6.8M | -$4.4M | -$6.1M | -$27.3M | -$1.6M | -$1.6M | -$1.9M | -$1.4M |
| Depreciation & Amortization | - | - | - | - | - | - | - | - | - | - | - | - | $24.7K | $40.7K |
| Operating Cash Flow | -$2.2M | -$3.8M | -$4.1M | -$3.3M | -$2.3M | -$2.9M | -$5.1M | -$3.3M | -$4.3M | -$1.6M | -$390.4K | -$390.4K | -$259.3K | -$225.2K |
| Share Buybacks | $28.2M | $13.6M | $0 | - | - | - | - | - | - | - | - | - | - | - |